Impact of pharmacokinetics and pharmacogenetics on the efficacy of pranlukast in Japanese asthmatics

Respirology

Volumn 14, Issue 6, 2009, Pages 822-827

  Asano, Koichiro ^a   Nakade, Susumu ^b   Shiomi, Tetsuya ^a   Nakajima, Takeshi ^a   Suzuki, Yusuke ^a   Fukunaga, Koichi ^a   Oguma, Tsuyoshi ^a   Sayama, Koichi ^a   Fujita, Hirofumi ^c   Tanigawara, Yusuke ^a   Ishizaka, Akitoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c Keiyu Hospital   (Japan)

Author keywords

Asthma; Leucotriene; Leukotriene C4 synthase; Pharmacogenetics; Pharmacokinetics

Indexed keywords

LEUKOTRIENE C4 SYNTHASE; PRANLUKAST;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; COMPARTMENT MODEL; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; JAPANESE; LUNG FUNCTION; MALE; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ALLELES; ANTI-ASTHMATIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ASTHMA; CHROMONES; FEMALE; FORCED EXPIRATORY VOLUME; GLUTATHIONE TRANSFERASE; HUMANS; JAPAN; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 69049085653     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01552.x     Document Type: Article

References (21)

1. Peters-Golden M, Henderson WR Jr. Leukotrienes. N. Engl. J. Med. 2007 357 : 1841 1854.
2. Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J. Allergy Clin. Immunol. 2007 120 : 1269 1275.
3. Asano K, Ishizaka A. Pharmacogenetics of anti-leukotriene drugs. Clin. Exp. Allergy Rev. 2008 8 : 45 9.
4. 4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT1 antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002 12 : 565 570.
5. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 2006 173 : 379 385.
6. 4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000 55 : S28 31.
7. 4 synthase A(-444)C polymorphism. Pediatr. Pulmonol. 2003 36 : 413 420.
8. Matsumoto I, Natsui K, Yamamoto R, Miyata Y. Identification of human P450 isoforms in the metabolism of ONO-1078 and the effect of ONO-1078 on human P450 metabolism. Gendai Iryousya 1999 31 : 132 139.
9. Brocks DR, Upward J, Hust R, Koester FE, Collie H et al. The pharmacokinetics of pranlukast in healthy young and elderly subjects. Int. J. Clin. Pharmacol. Ther. 1996 34 : 375 379.
10. Brocks DR, Upward JW, Georgiou P, Stelman G, Doyle E et al. The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers. Eur. J. Clin. Pharmacol. 1996 51 : 303 308.
11. Inoue R, Teramoto T, Nakade S, Okamoto H, Yukawa E et al. Population pharmacokinetics of pranlukast hydrate dry syrup in children with bronchial asthma. Allergol. Int. 2003 52 : 213 218.
12. Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y et al. Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. Drug Metab. Pharmacokinet. 2006 21 : 133 139.
13. Guidelines for the Diagnosis and Management of Asthma. NIH Publication 1997 : 97-4051.
14. Tamura G, Aizawa H, Nagai A, Inoue H. Common prediction equations of respiratory function tests from children to adults in Japan. Nihon Kokyuki Gakkai Zasshi 2007 45 : 526 542.
15. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet. Genomics 2007 17 : 189 196.
16. 4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am. J. Respir. Cell Mol. Biol. 2000 23 : 290 296.
17. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997 350 : 1599 1600.
18. Currie GP, Lima JJ, Sylvester JE, Lee DK, Cockburn WJ et al. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br. J. Clin. Pharmacol. 2003 56 : 422 426.
19. 4 synthase and cysteinyl leukotriene receptor 1 genes in Korean children with exercise-induced asthma (EIA). Clin. Exp. Allergy 2007 37 : 1487 1493.
20. Yukawa E, Mine H, Higuchi S, Aoyama T. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J. Pharm. Pharmacol. 1992 44 : 761 765.
21. Yukawa E, Suematu F, Yukawa M, Minemoto M, Ohdo S et al. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. Clin. Pharmacokinet. 2001 40 : 773 781.